{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-027273","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.681397+00:00","generated_at":"2026-05-16T13:29:47.942763+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Lipocine presents LPCN 2101 posters at AES meeting; no specific data disclosed","bullets":["Posters for LPCN 2101, a GABA A receptor PAM candidate for epilepsy, presented at AES Annual Meeting Dec 5-9, 2025.","Poster 99.1 covers clinical PK and tolerability; Poster 99.2 covers oral toxicokinetics for women with epilepsy.","No efficacy, safety, or numerical results included in the filing; exhibits referenced but not detailed.","LPCN 2101 is a novel oral neuroactive steroid anti-seizure medication candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-027273","json":"https://secwatch.observer/filing/0001493152-25-027273.json","markdown":"https://secwatch.observer/filing/0001493152-25-027273.md","text":"https://secwatch.observer/filing/0001493152-25-027273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225027273/0001493152-25-027273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225027273/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:29:47.942763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}